The respiratory effects of oral ethyl loflazepate in volunteers.
E J Fazackerley, N P Randall, B J Pleuvry, I Bradbrook, G E Mawer
Index: Br. J. Clin. Pharmacol. 23(2) , 183-7, (1987)
Full Text: HTML
Abstract
A volunteer study was undertaken to assess the respiratory effects of ethyl loflazepate, a new benzodiazepine, and to correlate these with plasma concentrations of the active metabolites. Twelve volunteers were given placebo, 2 mg ethyl loflazepate, and 6 mg ethyl loflazepate on separate occasions. Respiration and plasma metabolite levels were assessed hourly for 8 h and at 24 h. The 6 mg ethyl loflazepate treatment produced a significant decrease (P less than 0.02) in the ventilatory response to carbon dioxide at 5 h. However this did not equate with a peak in plasma metabolite concentrations which were maintained at a plateau level from 4 to 24 h.
Related Compounds
Related Articles:
2014-10-01
[Xenobiotica 44(10) , 893-901, (2014)]
2014-10-01
[Forensic Sci. Int. 243 , 99-106, (2014)]
2014-11-01
[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 970 , 1-7, (2014)]
2014-11-01
[J. Pharm. Biomed. Anal. 100 , 28-32, (2014)]
Analysis of benzodiazepines and their metabolites using DBS cards and LC-MS/MS.
2015-10-01
[Forensic Sci. Int. 255 , 137-45, (2015)]